Celltrion, Inc.

South Korea

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Feb 23, 2018
Prev close: 318,000
Feb 23, 2018
Market cap:
Market cap(USD):
Shares: 125.12M

Currency in KRW

Company profile

Market(Ticker): KRX(068270)
Health Technology
Full time employees: --

Business summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Company background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

In the news

Financial highlights

Dec 2017

  • Local currency
  • US Dollar
Revenue 949,080M
Gross profit 687,096M
Operating income 522,001M
Income before tax 505,748M
Net income 399,361M
Diluted EPS --
Dividends per share --
Total assets --
Total liabilities --
Total equity --
Operating cash flow --

Currency in KRW

Revenue 839.51M
Gross profit 607.77M
Operating income 461.73M
Income before tax 447.36M
Net income 353.25M
Diluted EPS --
Dividends per share --
Total assets --
Total liabilities --
Total equity --
Operating cash flow --

Currency in USD

Valuation measures

Dec 2017

PER 69.27
ROA --
ROE --
Operating margin 55.00%
Profit margin 42.07%

Key executive

  • Co-Chief Executive Officer & Director: Hyung-Ki Kim
  • Co-Chief Executive Officer & Director: Wu-Sung Ki
  • Head-Legal & Compliance Support: Sung-Han Lee
  • Vice President: Shin-Jae Jang
  • Vice President: Sang-Joon Lee

Share holders

  • SEO JUNG-JIN(21.7%)
  • Temasek Holdings Pte Ltd. (Investment Management)(14.2%)
  • Schroder Investment Management Ltd.(1.6%)
  • BlackRock Fund Advisors(1.5%)
  • The Vanguard Group, Inc.(1.5%)
  • Norges Bank Investment Management(0.9%)
  • OppenheimerFunds, Inc.(0.7%)
  • Celltrion Inc. Employee Stock Ownership ASSN.(0.7%)
  • Samsung Asset Management Co., Ltd.(0.6%)
  • BlackRock Advisors (UK) Ltd.(0.4%)


  • Website:
  • Address: 23 Academy-ro, Yeonsu-gu, Inchon, 22014, South Korea
  • Phone: +82.32.850.5000

Copyright © 2018 FactSet Research Systems Inc. All rights reserved.